Previous 10 | Next 10 |
Expands p ipeline with a cquisition of n ew tri-specific antibodies D ata readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Pur...
S cientific A dvisory B oard inaugurates new KOL support structure for Purple Biotech T hree advisors bring expertise as research ers , oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE NEWSWIR...
New preclinical data from study presented at the American A ssociation for Cancer Research 2023 Annual Meeting , 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TAS...
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to ov...
2023-03-24 07:18:21 ET Purple Biotech ( NASDAQ: PPBT ) on Friday said that the CEO, Gil Efron, has been hospitalized following a mishap and will be on medical leave , which is expected to last several months while he undergoes rehabilitation to recover from his injur...
Board of Directors appoints Isaac Israel , Board member and former CEO, as acting CEO Company’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biote...
Reduction in neutrophil extracellular traps (NETs) markers Potential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), ...
REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to...
Purple Biotech press release ( NASDAQ: PPBT ): Q4 GAAP EPADS of -$0.33 misses by $0.13 . As of December 31, 2022, Purple Biotech had cash and cash equivalents, short- and long-term deposits of $31.7 million, compared to $47.4 million on December 31, 2021. This cash position pr...
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd . (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT...
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Purple Biotech Ltd ADR (Sponsored) Level 3 Website:
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its ...
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...